Similar articles for PMID: 16460134

Year	Number of Results
1911	1
1920	2
1939	1
1972	1
1973	1
1995	1
1996	1
1998	4
1999	2
2000	3
2001	2
2002	2
2003	13
2004	11
2005	7
2006	10
2007	2
2008	9
2009	5
2010	3
2011	4
2012	4
2013	2
2014	2
2015	5
2016	3
2017	5
2018	7
2019	6
2020	8
2021	1
2022	6
2023	1
2024	0

1

Differential effects of atypical versus typical antipsychotic medication on earnings of schizophrenia patients : estimates from a prospective naturalistic study.

Salkever D, Slade E, Karakus M. Salkever D, et al. Pharmacoeconomics. 2006;24(2):123-39. doi: 10.2165/00019053-200624020-00003. Pharmacoeconomics. 2006. PMID: 16460134

2

Effects of antipsychotic medication on psychiatric service utilization and cost.

Rothbard A, Murrin MR, Jordan N, Kuno E, McFarland BH, Stroup TS, Morrissey JP, Stiles PG, Boothroyd RA, Merwin E, Shern DL. Rothbard A, et al. J Ment Health Policy Econ. 2005 Jun;8(2):83-93. J Ment Health Policy Econ. 2005. PMID: 15998980

3

Effectiveness and cost of atypical versus typical antipsychotic treatment in a nationwide cohort of patients with schizophrenia in Germany.

Stargardt T, Edel MA, Ebert A, Busse R, Juckel G, Gericke CA. Stargardt T, et al. J Clin Psychopharmacol. 2012 Oct;32(5):602-7. doi: 10.1097/JCP.0b013e318268ddc0. J Clin Psychopharmacol. 2012. PMID: 22926592

4

Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia.

Ascher-Svanum H, Zhu B, Faries D, Landbloom R, Swartz M, Swanson J. Ascher-Svanum H, et al. BMC Psychiatry. 2006 Feb 21;6:8. doi: 10.1186/1471-244X-6-8. BMC Psychiatry. 2006. PMID: 16504026 Free PMC article. Clinical Trial.

5

Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia : a 12- and 24-month follow-up from the e-STAR database in Spain.

Olivares JM, Rodriguez-Martinez A, Burón JA, Alonso-Escolano D, Rodriguez-Morales A; e-STAR Study Group. Olivares JM, et al. Appl Health Econ Health Policy. 2008;6(1):41-53. doi: 10.2165/00148365-200806010-00004. Appl Health Econ Health Policy. 2008. PMID: 18774869

6

Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care.

Stargardt T, Weinbrenner S, Busse R, Juckel G, Gericke CA. Stargardt T, et al. J Ment Health Policy Econ. 2008 Jun;11(2):89-97. J Ment Health Policy Econ. 2008. PMID: 18509216

7

The cost-effectiveness of atypicals in the UK.

Heeg B, Buskens E, Botteman M, Caleo S, Ingham M, Damen J, de Charro F, van Hout B. Heeg B, et al. Value Health. 2008 Dec;11(7):1007-21. doi: 10.1111/j.1524-4733.2008.00344.x. Epub 2008 May 16. Value Health. 2008. PMID: 18489517 Free article.

8

In the aftermath of CATIE: how should administrators value atypical antipsychotic medications?

Luchins DJ. Luchins DJ. Adm Policy Ment Health. 2006 Sep;33(5):541-3. doi: 10.1007/s10488-006-0049-z. Adm Policy Ment Health. 2006. PMID: 16688482

9

Antipsychotic prescription use and costs for persons with schizophrenia in the 1990s: current trends and five year time series forecasts.

Martin BC, Miller LS, Kotzan JA. Martin BC, et al. Schizophr Res. 2001 Mar 1;47(2-3):281-92. doi: 10.1016/s0920-9964(00)00108-0. Schizophr Res. 2001. PMID: 11278146

10

Cost-effectiveness of atypical antipsychotic medications versus conventional medication.

Hanrahan P, Luchins DJ, Fabian R, Tolley G. Hanrahan P, et al. Expert Opin Pharmacother. 2006 Sep;7(13):1749-58. doi: 10.1517/14656566.7.13.1749. Expert Opin Pharmacother. 2006. PMID: 16925502 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

125 results

Results by year